Nektar Therapeutics's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Nektar Therapeutics's ROI in the second quarter of 2026?
Nektar Therapeutics recorded a cumulative net loss of $-157 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -28.68%.

Within the Healthcare sector 359 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2181 to 3726.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	172.49 %	36.62 %	-29.58 %	-34.34 %	-41.14 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	1,024	706	227	235	136
Return On Investment (TTM)	-28.68 %	-48.51 %	-83.78 %	-60.45 %	-60.81 %
NKTR's Overall Ranking	# 3726	# 2181	# 3133	# 3447	# 3127
Seq. Investment Change TTM	68.12 %	66.42 %	-1.95 %	-0.67 %	-15.71 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-157	-158	-164	-121	-122

NKTR Company Profile >> Back to NKTR Roi Comparisons >> See Annual NKTR Return On Investment

Return On Investment NKTR's Ranking
Within:	No.
Industry	# 139
Sector	# 360
Overall	# 3726

Return On Investment Statistics
High	Average	Low
101.39 %	-32.29 %	-83.78 %
(Jun 30 2018)		(Dec 31 2025)

Financial Statements
Nektar Therapeutics's II. Quarter Investments	$ 1,024 Millions	NKTR's Balance sheet
Nektar Therapeutics's II. Quarter Income	$ -41 Millions	Quarterly NKTR's Income Statement
NKTR's Income by Division		See NKTR's Income by Division

NKTR Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	227	242	347	642	1,032
Y / Y Investment Growth	-6.43 %	-30.08 %	-46.02 %	-37.75 %	-6.93 %
Net Income in Millions	-164	-119	-276	-368	-524
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-72.32 %	-49.07 %	-79.61 %	-57.32 %	-50.76 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NKTR's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NKTR's Competitors
Subscribers only: Roi for Nektar Therapeutics's Suppliers
Subscribers only: Return On Investment for NKTR's Customers

Other Ratios
NKTR's Roa	NKTR's Inventory Turnover Ratio	NKTR's Growth Rates	NKTR's Dividend Statistics
	NKTR's Profitability Ratios	NKTR's Asset Turnover Ratio	NKTR's Dividend Growth
NKTR's Roe	NKTR's Valuation Ratios	NKTR's Financial Strength Ratios	NKTR's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:10:40+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.